Literature DB >> 8515307

Economic consequences of surfactant therapy.

A I Eidelman1.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8515307

Source DB:  PubMed          Journal:  J Perinatol        ISSN： 0743-8346            Impact factor:   2.521


× No keyword cloud information.
  3 in total

1.  A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.

Authors:  H Walti; M Monset-Couchard
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

2.  Economic outcomes of colfosceril palmitate rescue therapy in infants weighing 1250g or more with respiratory distress syndrome: results from a randomised trial.

Authors:  M E Backhouse; J A Mauskopf; D Jones; D E Wold; R Schumacher; R Cotton; W A Long
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

3.  A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa.

Authors:  Carlos G Guardia; Fernando R Moya; Sunil Sinha; Phillip D Simmons; Robert Segal; Jay S Greenspan
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.